Brochure
10 Sep 2024
Institutional One Pager
PDF 1.0 MB
Find out more information about SOMAÍ Pharmaceuticals
Content provided by our supplier
Somai Pharmaceuticals
-
PT
-
2022On CPHI since
-
1Certificates
-
25 - 49Employees
Company types
Primary activities
Other Content from Somai Pharmaceuticals (9)
-
News SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal
SOMAÍ Pharmaceuticals announces two significant partnerships with Canymed GmbH and Grünhorn, as part of its entry into the German market.
-
News SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany
SOMAÍ Pharmaceuticals and Canify AG announce their strategic partnership to introduce a differentiated cannabinoid-based product line in Germany
-
News SOMAÍ Pharmaceuticals Introducing the U.S. Award-Winning Airo Brand to European and Australian Markets
SOMAÍ Pharmaceuticals to manufacture and distribute Airo Brands’ products in Australian, German, Polish & Swiss medical markets
-
News SOMAÍ Pharmaceuticals Acquires RPK Biopharma (Holigen), Reinforcing Global Leading Position in Medicinal Cannabis Sector
SOMAÍ Pharmaceuticals Unipessoal LDA ("SOMAÍ"), an EU-GMP European pharmaceutical and biotech company distributing cannabinoid-containing pharmaceuticals globally, today announced it has entered into a definitive agreement with AKANDA Corp. (U.S. NASDAQ: AKAN), an international medical cannabis company, to acquire 100% off of the issued and outstanding shares of its Portuguese subsidiary RPK Biopharma (Holigen). The acquisition will significantly accelerate SOMAÍ's global leadership, improving the Company's ability to deliver a ground-breaking differentiated cannabinoid-containing product portfolio to meet patients' needs worldwide. -
News SOMAÍ Pharmaceuticals Introduces UK to The Most Complete Cannabis-Based Product Portfolio Following a Distribution Deal
SOMAÍ Pharmaceuticals Signs Distribution Deal with Grow Pharma for UK’s Most Comprehensive Range of Cannabis-Based Medicines
-
News SOMAÍ Group, and its subsidiary, RPK Biopharma expand Cookies partnership to include Europe and the UK
SOMAÍ Group and its subsidiary, RPK Biopharma expanded their existing partnership with Cookies Creative Consulting & Promotions, Inc. to include additional territories for the dried flower portfolio and manufacture different extract products. The amendment enables SOMAÍ to exclusively cultivate, manufacture, and distribute Cookies branded products through its distribution partners in UK, Germany, Portugal, Poland, Malta, and the Czech Republic. -
News Leading Canadian Cannabis Brand Ghost Drops Enters into an Agreement with SOMAÍ Group for Global Distribution
The partnership opportunely positions Ghost Drops and SOMAÍ Group to succeed in the EU, UK, and Australian Cannabis Markets
-
News SOMAÍ Pharmaceuticals Expands Its Most Comprehensive Medicinal Cannabis Portfolio With Mint Oral Solutions Launch
SOMAÍ Pharmaceuticals is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the UK. -
News Cosma S.A. and SOMAÍ Pharmaceuticals partner to Revolutionize Poland with the most Innovative Cannabis-Based Solutions
Cosma S.A. and SOMAÍ Pharmaceuticals partner to Revolutionize the Polish medical cannabis market with the most Innovative Cannabis-Based Solutions
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance